Hi, my name is Mohamed Bajajovic, I'm an associate professor of medicine, director of multiple myeloma and multidisciplinary amyloidosis programs at Vanderbilt University Medical Center in Nashville, Tennessee. This EHA meeting and the just recently completed ASCO meeting, we presented some of the data on a tantamic, which is a BCMA-specific antibody, long-term data on Q4 weekly dosing of this innovative, you could say, next generation BIS-specific antibody. So in over 100 patients that were given this BIS-specific antibody every four weekly, medium progression free survival has not been met yet after at least medium follow-up of 13 months. Overall response rate is in the range of 60, mid-60 to mid-70 percent and is overall similar among different subgroups of patients including prior lines of therapy, age and different ethnic subgroups. What's notable to mention is that because of the specific design of this BIS-specific antibody which includes low affinity CD3 binding which helps reduce the CRS rates as well as the silenced FC tail which allows this antibody to be given at prolonged periods of time every weekly or in this case every four weekly, this has ended up generating very safe CRS profile which is the lowest compared to any other BIS-specific that's prophylaxed without to salizumab just with dexamethasone. Overall CRS rates of 30 percent of which 26 percent is grade one which is generally treated with Tylenol alone and then only four percent of grade two, no grade three events. The step-up dosing was developed in the phase 1b study where a small 2 milligram dose was given and prophylaxed with 10 milligrams of dexamethasone on cycle 1 day 1 followed by a full dose of 60 milligrams with 36 milligrams of dexamethasone per medication and then cycle two onward every four weeks. This is fairly attractive and beneficial for patient convenience and obviously in terms of CRS rate this is a very low CRS incidence, vast majority of which is grade one which is easily managed and this can end up being something which is very attractive for those sites that I haven't onboarded yet with any other BIS-specific. It's important to note that this data has laid grounds for the registration of Trevino phase 3 trial which is global, currently undergoing randomizing one-to-one between a tantamic Q4 weekly with a day one, day four step-up dosing in cycle one and then Q4 weekly afterwards versus three standard care options per PI discretion including high dose Kyprolis dex or elotuzumal promalidomide dex or selenaxor velcade dex. Also important to note that this is in patients with at least two prior lines of therapy and should the PIs choose to pick one of the control arms, should it be Kyprolis, patients must not be previously exposed to Kyprolis or if it's elopom they can be previously exposed to elo or pom. When it comes to selenaxor velcade there can't be any prior selenaxor exposure. Velcade is allowed previously but at least PR response rate and at least six months of washout that's also expected to be changed soon to make the eligibility and accrual more friendly. So this is currently as I said ongoing phase 3 trial and has a potential of potentially bringing a tantamag in this very convenient Q4 weekly safe formulation for patients across the globe.
HealthTree • July 2, 2025